Table 2.

Combination of BZ with CFZ against B16-F1 cell growth in MTT assay in vitro.

Drug		Cell Viability (Fa) a	Parameters b			CI c	DRI d		Comments
BZ (nM)	CFZ (nM)		m	Dm	r		BZ	CFZ
5	-	0.772	–2.029	8.397	–0.979
10	-	0.334
20	-	0.169
-	5	0.937	–2.002	18.91	–0.999
-	10	0.769
-	20	0.481
5	5	0.376	–1.058	5.263	–0.926	0.669	2.16	4.87	Moderate synergism, favorable dose-reduction
10	10	0.147				0.720	2.00	4.55
20	20	0.122				1.295	1.11	2.53	Antagonism, no dose- reduction for BZ but favorable for CFZ
		Simulation
		0.05				1.703	0.84	1.94	Antagonism No or not favorable dose-reduction for BZ but favorable for CFZ
		0.10				1.216	1.18	2.70
		0.25				0.742	1.94	4.40	Slight synergism, favorable dose-reduction
		0.50				0.453	3.19	7.19	Moderate synergism, favorable dose-reduction
		0.75				0.276	5.24	11.7	High synergism, favorable dose-reduction
		0.90				0.168	8.62	19.1
		0.95				0.120	12.1	26.7

This table is formed from the output results generated by CompuSyn Report. ^a. Dose and data for growth inhibition effect (Fa) were obtained from the MTT assay (average value of quadruplicate) and applied to CompuSyn analysis. ^b. Parameters were derived from the median-effect equation and plot. The m value is slope; Dm is IC₅₀ for BZ or CFZ; and r is linear correlation coefficient. ^c. Combination index (CI) was calculated from the CI equation algorithms using CompuSyn software. CI = 1, CI < 1, and CI > 1 indicate additive effect, synergism, and antagonism, respectively. ^d. Dose-reduction index (DRI) was calculated from the DRI equation and algorithm using CompuSyn software. DRI = 1, DRI > 1, and DRI < 1 indicate no dose-reduction, favorable dose-reduction, and not favorable dose-reduction, respectively, for each drug in the combination.